Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Account Payables

Amounts the company owes suppliers for goods and services received.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 13.0% from a year ago

Account payables stood at $2.97M at the end of Q1 FY2026, up 13.0% from a year earlier and up 412.8% from the prior quarter. Over 3 fiscal years it compounded at -32.4% a year.

Context

  • Account payables amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +13.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.97M+412.8% QoQ
Last fiscal yearDec 2025
$579K-85.6% YoY
Year agoMar 2025
$2.63M+13.0% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%——
1 year-85.6%——
3-year CAGR-32.4%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
579K USD
Year-over-year change
-85.6%
4-year CAGR
-38.7%

Account Payables vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +13.0% is the 4th highest of 11, against a peer median of -14.0%.
  • Account payables amounts to 2.2% of total assets for BDTX, versus a peer median of 1.8%.
BDTX Competitors
Account Payables for BDTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$1.45B USD+110780.3%-21.2%0.7%
IVAInventiva S.A.Dec 2025€26.01M EUR-20.9%+10.3%10.4%
FENCFennec Pharmaceuticals Inc.Mar 2026$6.28M USD+19.0%+24.6%8.7%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$4.49M USD+75.8%+100.0%4.6%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$4.36M USD-8.3%-31.3%1.4%
ABEOAbeona Therapeutics Inc.Mar 2026$4.07M USD-18.9%+63.3%2.1%
CRBUCaribou Biosciences, Inc.Mar 2026$3.5M USD-9.6%+71.5%2.4%
FHTXFoghorn Therapeutics Inc.Mar 2026$3.32M USD-18.5%-7.6%1.5%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$2.97M USD+13.0%-32.4%2.2%
TNYATenaya Therapeutics, Inc.Mar 2026$1.91M USD-62.2%-28.0%1.4%
AVTXAvalo Therapeutics, Inc.Mar 2026$356K USD-47.7%-63.8%0.4%
Peer median (excluding BDTX) —-14.0%+1.4%1.8%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents65.8M34.32M56.22M36.44M20.99M
Short-term Investments143.99M88.49M75.18M62.14M107.66M
Net Receivables00000
Inventory00000
Other Current Assets04.9M2.63M2.6M3.79M
Total Current Assets215.7M127.71M134.03M101.18M132.44M
Property, Plant & Equipment (Net)30.74M27.38M23.71M20.4M9.67M
Goodwill00000
Intangible Assets00000
Long-term Investments0000829K
Tax Assets00000
Other Non-current Assets1.24M1.17M823K1.07M73K
Total Non-current Assets31.98M28.55M24.53M21.46M10.57M
Total Assets247.68M156.26M158.57M122.64M143.01M
Account Payables4.11M1.88M2.32M4.01M579K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities23.64M15.26M19.65M20.57M15.73M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities28.14M25.3M22.19M18.78M15.07M
Total Liabilities51.78M40.56M41.83M39.36M30.8M
Common Stock5K5K7K7K8K
Retained Earnings(243.82M)(334.99M)(417.43M)(487.11M)(464.74M)
Accumulated OCI(414K)(1.82M)(27K)24K101K
Other Stockholders Equity00000
Minority Interest00000
Total Equity195.9M115.7M116.74M83.29M112.21M
Total Debt28.46M28.14M25.3M22.19M18.78M
Net Debt(37.34M)(6.18M)(30.92M)(14.25M)(2.21M)

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.